Xcout IntelSign inSubscribe

ILIKA PLC competitors & alternatives

IKABattery TechnologyRomsey, United Kingdom

The 12 closest competitors and alternatives to ILIKA PLC among battery technology companies — ranked by similarity to what ILIKA PLC actually does, not by market-cap band.

$66.7MMarket cap
70Employees
12Competitors listed

Subscribe to see ILIKA PLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

About ILIKA PLC

Ilika plc, an enterprise established in 2004 with its headquarters in Romsey, United Kingdom, focuses on the conception, refinement, and commercial production of solid-state battery technology. These advanced power cells are distributed globally under their Stereax brand, primarily serving markets in the UK, Asia, mainland Europe, and North America. The company's battery solutions find application across numerous sectors, such as industrial Internet of Things, medical apparatus, various transportation systems including electric vehicles, and portable consumer electronics, as well as supporting smart city initiatives.

ILIKA PLC at a glance

ILIKA PLC is a battery technology company headquartered in Romsey, United Kingdom, founded in 2010. It is publicly listed (IKA) with a market capitalisation of $66.7M. Xcout tracks 5 named people at ILIKA PLC, including Graeme Purdy (Chief Executive Officer).

ILIKA PLC leadership

  • Graeme PurdyChief Executive Officer
  • Jason StewartChief Financial Officer
  • Prof. Keith JacksonChairman
  • Dr Monika BiddulphNon-Executive Director
  • Jeremy MillardNon-Executive Director

Top 12 ILIKA PLC competitors

Ranked by semantic similarity — how close each company is to ILIKA PLC by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.

MESOBLAST LTDMESO · Regenerative MedicineMelbourne, Australia
62% matchPublic

Regenerative Medicine

Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.

Market cap$1.9B
Employees73
MESOBLAST LTD competitors & alternatives →

Analyze another company

Search any company we track to see its competitive set.

Or describe a company

Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.

See the full profile of ILIKA PLC and its market

Funding, investors, tech stack, hiring signals, leadership and corporate events — for ILIKA PLCand every competitor above — in one live dashboard.

Subscribe to Xcout Intel →